Sanofi’s Zynquista (sotagliflozin) and Dupixent (dupilumab) Receives CHMP Recommendation for Type 1 Diabetes and Asthma

 Sanofi’s Zynquista (sotagliflozin) and Dupixent (dupilumab) Receives CHMP Recommendation for Type 1 Diabetes and Asthma

Sanofi’s Zynquista (sotagliflozin) and Dupixent (dupilumab) Receives CHMP Recommendation for Type 1 Diabetes and Asthma

Shots:

  • Zynquista’s CHMP recommendation is based on P-III TANDEM study assessing Zynquista (200mg &400mg) vs insulin in 3,000 patients with T1D mellitus. The study resulted in reduction in blood sugar level and systolic BP @24wks. & improvement in time to maintain targeted blood sugar range
  • Dupixent ‘s CHMP recommendation is based on P-III QUEST and VENTURE studies assessing Dupixent vs PBO in 2,888 patients with asthma. The studies resulted in reduction in asthma attacks (exacerbations), dependency on corticosteroids & improvement in lung function
  • Zynquista (200mg &400mg, PO) is an SGLT1 & SGLT2 inhibitor, co-developed by Sanofi and Lexicon with awaited US and EU approval. Dupixent is a mAb, inhibitor of IL-4 & IL-13, co-developed by Sanofi and Regeneron and has received the US FDA & EU approval in asthma & atopic dermatitis respectively

Click here, Click here, to read full press release/ article | Ref: Sanofi | Image: Evaluate Pharma

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post